| Literature DB >> 33153493 |
Ellen Dalen Arnstad1,2, Johanne Marie Iversen3, Martin Uglem4,5, Mia Glerup6, Pål Richard Romundstad7, Trond Sand4,5, Marite Rygg8,9.
Abstract
BACKGROUND: To study for the first-time, pain perception, pain sensitivity, and self-reported pain in young adults with long disease duration of juvenile idiopathic arthritis (JIA) compared with controls.Entities:
Keywords: Juvenile idiopathic arthritis (JIA); Long-term outcomes; Pain perception; Pain sensitivity; Pain sensitization; Pain threshold; Quantitative sensory testing (QST); Self-reported pain; Young adults
Mesh:
Year: 2020 PMID: 33153493 PMCID: PMC7643261 DOI: 10.1186/s13075-020-02345-2
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Clinical characteristics of the juvenile idiopathic arthritis (JIA) cohort and control group
| Characteristics | Juvenile idiopathic arthritis | Control | ||||
|---|---|---|---|---|---|---|
| Total no. assessed | Values | Total no. assessed | Values | |||
| Female sex | 96 | 68 | (71) | 109 | 77 | (71) |
| Fulltime school or work | 94 | 73 | (78) | 109 | 86 | (79) |
| Age at visit, years, median (IQR) | 96 | 22.7 | (18.7–26.2) | 109 | 23.5 | (20.2–26.7) |
| Age at disease onset, years, median (IQR) | 96 | 6.4 | (2.7–11.7) | – | – | |
| Disease duration at visit, years, median (IQR) | 96 | 16.1 | (14.2–17.1) | – | – | |
| Oligoarticular JIA at onset | 96 | 51 | (53) | – | – | |
| Oligoarticular JIA at visita | 96 | 45 | (47) | – | – | |
| Not in remission at visitb | 96 | 53 | (55) | – | – | |
| DMARDs and/or biologics at visit | 96 | 34 | (35) | – | – | |
| HAQ, median (IQR) | 96 | 0 | (0.0–0.125) | – | – | |
| Women: hormonal contraceptives | 68 | 42 | (62) | 74 | 48 | (65) |
| Women: days since LMP, median (IQR) | 54 | 14 | (6–26) | 69 | 19 | (9–39) |
| Alcohol consumption at day of visitc | 95 | 0 | (0) | 109 | 2 | (2) |
| Use of tobacco at day of visitc | 93 | 21 | (23) | 106 | 22 | (21) |
| Consumption of coffee/tea/cola at day of visitc | 95 | 36 | (38) | 109 | 28 | (26) |
| Pain or psychotropic medication at day of visitd | 95 | 4 | (4) | 107 | 2 | (2) |
| SF-36 PCS, mean (± SD) | 96 | 51.1 | (± 9.5) | 109 | 55.1 | (± 7.9) |
| SF-36 MCS, mean (± SD) | 96 | 47.7 | (± 11.6) | 109 | 47.5 | (± 9.7) |
Unless otherwise stated, values indicate numbers (%); no. numbers; IQR interquartile range, 1st–3rd; DMARDs disease-modifying anti-rheumatic drugs; biologics biologic drugs; HAQ Health Assessment Questionnaire, 0–3 (0 = lowest, 3 = highest); LMP last menstrual period; SD standard deviation; SF-36 Short-form 36 Health Status Questionnaire, 0–100 (< 40 poor health); PCS physical component summary; MCS mental component summary
aPersistent (no. = 27) and extended (no. = 18) oligoarticular disease
bNot in remission off medication for ≥ 12 months according to the definition by Wallace et al.
cConsumption after 00.00 on the day of visit
dPain or psychotropic medication after 00.00 on the day of visit, including JIA: ibuprofen (n = 1), methylphenidate (n = 2), and prednisolone (n = 1) and control: paracetamol (n = 1) and lisdexamfetamine (n = 1)
Clinical characteristics of subgroups in the juvenile idiopathic arthritis (JIA) cohort
| Characteristics | Remission off medicationa | Inactive diseasea | Active diseasea |
|---|---|---|---|
| Values | Values | Values | |
| Female sex, | 25 (58) | 15 (75) | 28 (85) |
| Age at onset, years, median (IQR) | 8.3 (3.1–11.8) | 3.7 (2.2–8.5) | 7.0 (2.6–12.3) |
| Age at visit, years, median (IQR) | 24.2 (20.3–26.5) | 18.8 (17.5–21.8) | 22.7 (19.2–26.5) |
| Systemic arthritis, | 1 (2) | – | – |
| Oligoarticular persistent, | 17 (40) | 5 (25) | 5 (15) |
| Oligoarticular extended, | 3 (7) | 5 (25) | 10 (30) |
| Polyarthritis RF positive arthritis, | – | 1 (5) | 1 (3) |
| Polyarthritis RF negative arthritis, | 13 (30) | 4 (20) | 6 (18) |
| Psoriatic arthritis, | 1 (2) | – | 3 (9) |
| Enthesitis-related arthritis, | 3 (7) | 2 (10) | 2 (6) |
| Undifferentiated arthritis, | 5 (12) | 3 (15) | 6 (18) |
| DMARDs ever, | 9 (18) | 19 (37) | 23 (45) |
| Biologics ever, | 2 (5) | 13 (35) | 22 (60) |
| HAQ, median (IQR) | 0 (0–0) | 0 (0–0.125) | 0.125 (0–0.25) |
| SF-36 PCS, mean (± SD) | 55.7 (7.0) | 52.2 (7.4) | 44.6 (9.8) |
| SF-36 MCS, mean (± SD) | 48.8 (12.3) | 44.6 (12.7) | 48.1 (10.0) |
N numbers; IQR interquartile range, 1st–3rd; RF rheumatoid factor; DMARDs disease-modifying anti-rheumatic drugs; Biologics biologic drugs; HAQ Health Assessment Questionnaire, 0–3 (0= lowest, 3 = highest); SD standard deviation; SF-36 Short-form 36 Health Status Questionnaire, 0–100 (< 40 poor health); PCS physical component summary; MCS mental component summary
aDisease status according to the definition by Wallace et al. Remission off medication for ≥ 12 months. Inactive disease on medication for less than 6 months or inactive disease off medication for less than 12 months or remission on medication (inactive disease on medication for more than 6 months). Active disease flare or continuous active disease
bJIA category according to the International League of Associations for Rheumatology (ILAR) classification criteria
Fig. 1An illustration of the distribution of cold, heat, and pressure pain thresholds (CPT, HPT, and PPT) at upper and lower limb in young adults with juvenile idiopathic arthritis (JIA) and age- and sex-matched controls. The dot-plot illustrating the distribution within each group as dots, and the group median indicated with the horizontal spiked line
Thermal pain thresholds and pressure pain thresholds among juvenile idiopathic arthritis (JIA) and controls*
| Cold pain threshold | Heat pain threshold | Pressure pain threshold | |||||
|---|---|---|---|---|---|---|---|
| Absolute temperature °C (95% CI) | Absolute temperature °C (95% CI) | Kilopascal (95% CI) | |||||
| Upper limb | Lower limb | Upper limb | Lower limb | Upper limb | Lower limb | ||
| Control | 109 | 15.9 (13.8, 18.0) | 13.2 (11.1, 15.3) | 44.3 (43.6, 45.0) | 44.9 (44.3, 45.4) | 1029 (999, 1059) | 760 (726, 794) |
| JIA (total group)b | 96 | 15.5 (13.1, 17.8) | 13.4 (11.1, 15.8) | 44.0 (43.1, 44.8) | 44.8 (44.2, 45.4) | 888 (846, 930) | 702 (670, 734) |
| JIA | |||||||
| Remission off med.c | 43 | 14.3 (10.7, 17.8) | 11.8 (8.2, 15.4) | 43.6 (42.2, 45.0) | 44.8 (43.8, 45.8) | 893 (823, 962) | 731 (674, 788) |
| Inactive diseasec | 20 | 16.9 (11.9, 22.0) | 17.4 (12.4, 22.4) | 44.2 (42.4, 46.0) | 44.9 (43.5, 46.3) | 836 (761, 910) | 626 (574, 677) |
| Active diseasec | 33 | 16.2 (12.4, 20.0) | 13.1 (9.2, 17.0) | 44.3 (43.1, 45.4) | 44.6 (43.9, 45.3) | 910 (842, 978) | 707 (662, 752) |
*Multilevel modeling with predicted values as absolute temperature with 95% CI, adjusted for age and sex
CI confidence interval, p p value comparing controls with JIA disease group (either total group or according to disease status)
aA substantial number were censored because the participants did not reach their cold pain thresholds due to floor temperature of the hardware was 5 °C; 212 (28%) in the JIA group and 198 (23%) in the control group. We accounted for these censored responses in the statistical analyses
bSeparate multilevel model of the total JIA cohort
cDisease status according to the definition by Wallace et al. Remission off med. remission off medication for ≥ 12 months, Inactive disease inactive disease on medication for less than 6 months or inactive disease off medication for less than 12 months or remission on medication (inactive disease on medication for more than 6 months). Active disease flare or continuous active disease
Fig. 3Pain scores during 120-s continuous suprathreshold heat pain stimulation in young adults with juvenile idiopathic arthritis (JIA) and age- and sex-matched controls. Pain scores were measured with numeric rating scale (NRS), range 0–10 (0 = no pain, 10 = unbearable pain). The estimated margins of the multilevel model are graphically illustrated with time on the x-axis and NRS scores on the y-axis. In both groups, the NRS scores increased during the 120-s stimulation, but it was a trend towards steeper increase in the JIA group
Fig. 2Graphic illustration of cold, heat, and pressure pain thresholds (CPT, HPT, and PPT) in JIA and controls as estimated margins with 95% CI from the multilevel models, adjusted for age and sex. The y-axis represents absolute temperature (°C) in CPT and HPT and kilopascal (kPa) in PPT. Since the censored CPT values are accounted for in the estimated margins of CPT, these results are not directly comparable with the results in Fig. 1 and Supplementary Table S2
Self-reported pain among participants with juvenile idiopathic arthritis (JIA) and controls
| Pain intensitya | Pain interferenceb | VAS current joint-related painc | VAS disease-related paind | ||
|---|---|---|---|---|---|
| Control | 109 | 2.2 (± 1.3) | 1.4 (± 0.7) | 0.2 (± 1.0) | – |
| JIA (total group) | 96 | 2.5 (± 1.3) | 1.7 (± 1.0) | 1.0 (± 1.7) | 1.7 (± 2.2) |
| JIA | |||||
| Remission off med.e | 43 | 1.9 (± 1.1) | 1.5 (± 1.0) | 0.5 (± 1.2) | 0.4 (± 1.2) |
| Inactive diseasee | 20 | 2.7 (± 1.3) | 1.5 (± 0.9) | 0.9 (± 1.7) | 1.9 (± 2.0) |
| Active diseasee | 33 | 3.3 (± 1.2) | 2.1 (± 0.9) | 1.8 (± 1.9) | 3.2 (± 2.5) |
Values are mean (± SD) unless otherwise indicated; n numbers, VAS visual analog scale
aSelf-reported body pain intensity during the last 4 weeks, measured with SF-36 questionnaire, 1–6 (1 = no pain, 6 = very severe pain)
bSelf-reported pain influence on daily activities during the last 4 weeks, measured with SF-36 questionnaire, 1–5 (1 = not at all, 5 = extremely)
cSelf-reported current joint-related pain the day of visit, measured with 10 cm continuous VAS (0 = no pain, 10 = unbearable pain). One of 33 participants with active disease did not fill in the VAS current joint-related pain
dSelf-reported disease-related pain last week measured with 21 numbered 0–10 VAS (0 = no pain, 10 = unbearable pain)
eDisease status according to the definition by Wallace et al. Remission off med. remission off medication for ≥ 12 months. Inactive disease inactive disease on medication for less than 6 months or inactive disease off medication for less than 12 months or remission on medication (inactive disease on medication for more than 6 months). Active disease flare or continuous active disease